BridgeBio reports positive phase 3 results for LGMD2I/R9 drug BBP-418

March 11, 2026 2:00 PM

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported positive interim results from its phase 3 FORTIFY trial of BBP-418, an oral treatment ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found